Korean biopharmaceutical companies urged to boost revenue

Published: 2013-04-23 07:00:00

Updated: 2013-04-23 07:00:00

The founder and chief executive officer of Celltrion, Seo Jung-jin, made a surprising announcement last Tuesday stating that he would offload his 97.3 percent controlling stake in the company. He said he plans to sell the pharmaceutical company to a multinational drugmaker due to constant predato...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK